Stock Research for RDHL

RDHL

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

RDHL Stock Chart & Research Data

The RDHL chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the RDHL chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


RDHL Due diligence Resources & Stock Charts

The RDHL stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View RDHL Detailed Price Forecast - CNN Money CNN View RDHL Detailed Summary - Google Finance
Yahoo View RDHL Detailed Summary - Yahoo! Finance Zacks View RDHL Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View RDHL Trends & Analysis - Trade-Ideas Barrons View RDHL Major Holders - Barrons
NASDAQ View RDHL Call Transcripts - NASDAQ Seeking View RDHL Breaking News & Analysis - Seeking Alpha
Spotlight View RDHL Annual Report - CompanySpotlight.com OTC Report View RDHL OTC Short Report - OTCShortReport.com
TradeKing View RDHL Fundamentals - TradeKing Charts View RDHL SEC Filings - Bar Chart
WSJ View Historical Prices for RDHL - The WSJ Morningstar View Performance/Total Return for RDHL - Morningstar
MarketWatch View the Analyst Estimates for RDHL - MarketWatch CNBC View the Earnings History for RDHL - CNBC
StockMarketWatch View the RDHL Earnings - StockMarketWatch MacroAxis View RDHL Buy or Sell Recommendations - MacroAxis
Bullish View the RDHL Bullish Patterns - American Bulls Short Pains View RDHL Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View RDHL Stock Mentions - StockTwits PennyStocks View RDHL Stock Mentions - PennyStockTweets
Twitter View RDHL Stock Mentions - Twitter Invest Hub View RDHL Investment Forum News - Investor Hub
Yahoo View RDHL Stock Mentions - Yahoo! Message Board Seeking Alpha View RDHL Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for RDHL - SECform4.com Insider Cow View Insider Transactions for RDHL - Insider Cow
CNBC View RDHL Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for RDHL - OTC Markets
Yahoo View Insider Transactions for RDHL - Yahoo! Finance NASDAQ View Institutional Holdings for RDHL - NASDAQ


Stock Charts

FinViz View RDHL Stock Insight & Charts - FinViz.com StockCharts View RDHL Investment Charts - StockCharts.com
BarChart View RDHL Stock Overview & Charts - BarChart Trading View View RDHL User Generated Charts - Trading View




Latest Financial News for RDHL


RedHill Gets Two New Patents for Crohn's Disease Candidate
Posted on Thursday July 05, 2018

RedHill Biopharma (RDHL) announces allowances of two new patents from the United States Patent and Trademark Office and the European Patent Office for its Crohn's disease candidate, RHB-104.


RedHill Biopharma (RDHL) Catches Eye: Stock Jumps 5.4%
Posted on Monday July 02, 2018

RedHill Biopharma (RDHL) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.


RedHill Biopharma Announces Allowance of Two New RHB-104 Patents Ahead of Top-Line Phase III Results for Crohn’s Disease
Posted on Monday July 02, 2018

TEL-AVIV, Israel and RALEIGH, N.C., July 02, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal (GI) diseases, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) and an Intention to Grant from the European Patent Office (EPO) for two new patents covering RHB-104, expected to be valid until at least February 5, 2029, once granted. The development of RHB-104 for Crohn’s disease is based on the hypothesis that Crohn’s disease is caused by Mycobacterium avium subspecies paratuberculosis (MAP) infection in susceptible patients.


Jaguar Health (NASDAQ: JAGX) Subsidiary Napo Pharmaceuticals and RedHill Biopharma Enter U.S. Co-Promotion Agreement for Mytesi, Napo's FDA-Approved Drug Product
Posted on Thursday June 28, 2018

SAN FRANCISCO, CA / ACCESSWIRE / June 28, 2018 / Napo Pharmaceuticals, Inc. (Napo), a human health company developing and commercializing novel gastrointestinal prescription products from plants used traditionally in rainforest areas, and a wholly-owned subsidiary of Jaguar Health, Inc. (JAGX) (Jaguar), today announced that it has entered into an agreement (the Agreement) with RedHill Biopharma Ltd. (RedHill) (RDHL), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal diseases and cancer, to establish a U.S. co-promotion program for Mytesi® (crofelemer 125 mg delayed-release tablets), Napo's FDA-approved drug, for the current approved indication. Mytesi is indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).


Stock Market & Investing Books

Enter a stock symbol to view the stock details.